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Abstract
Purpose New-onset diabetes after transplantation (NODAT)
is a major complication after kidney transplantation. The
risk factors for NODAT include the use of calcineurin inhib-
itors as part of the immunosuppressive regimen, among
which tacrolimus has the most pronounced diabetogenic
effect. Both NODAT and type 2 diabetes mellitus (T2DM)
share several risk factors. Recent studies have identified a
number of common genetic variants associated with in-
creased risk of T2DM. Here we report the results of our
study on the potential effect of single nucleotide polymor-
phisms (SNPs) previously associated with T2DM on the risk
of NODAT in kidney transplant patients medicated with
tacrolimus.
Methods Seven SNPs in six genes known to increase the
risk of T2DM in Caucasians were genotyped by means of
TaqMan assays in 235 kidney transplant patients medicated
with tacrolimus: rs4402960 and rs1470579 in IGF2BP2;
rs1111875 in HHEX; rs10811661 upstream of CDKN2A/B;
rs13266634 in SLC30A8; rs1801282 in PPARG; rs5215 in
KCNJ11. The TCF7L2 rs7903146 SNP was also included in
the multivariate analysis.
Results None of the analyzed SNPs was significantly asso-
ciated with the risk of NODAT. However, the IGF2BP2
rs4402960 T allele was present significantly more frequently
among patients diagnosed with NODAT more than 2 weeks
after transplantation (p00.048). Mean (± standard deviation)
number of the analyzed alleles tended to be lower in patients
without NODAT (6.19±1.71) than in NODAT patients
(6.58±1.1.95; p00.09) and significantly lower compared
to late-onset NODAT patients (7.03±1.88; p00.018). Mul-
tivariate analysis confirmed the significance of ‘diabetogen-
ic’ allele number in late-onset NODAT development [odds
ratio (OR) 1.37, 95 % confidence interval (CI) 1.05–1.78;
p00.017]. Additionally, individuals carrying >7 of the ana-
lyzed ‘diabetogenic’ alleles were at a significantly higher
risk of NODAT (OR 2.17, 95 % CI 1.18–3.99; p00.015).
Conclusions Complex analysis of genotypes increasing the
risk of diabetes may lead to the identification of NODAT
susceptibility predictors.
Keywords NODAT . Kidney transplantation . Single
nucleotide polymorphisms . Type 2 diabetes mellitus
Introduction
New-onset diabetes after transplantation (NODAT) is one of
the major complications after kidney transplantation. The
term ‘NODAT’ has replaced the older term ‘post-transplant
diabetes mellitus’ (PTDM) to differentiate new-onset diabe-
tes from diabetes developed prior to transplantation [1]. It is
now widely accepted that NODAT leads to graft failure and
promotes cardiovascular disease, the main cause of death in
kidney transplant recipients [2]. The incidence of NODAT
in patients after solid organ transplantation reported in a
large meta-analysis ranged from 2 to 50 % at 1-year post-
transplantation [3]. The pathophysiology of NODAT closely
mimics that of type 2 diabetes mellitus (T2DM), with both
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diseases characterized by a combination of insulin resistance
and insulin hyposecretion. However, insulin hyposecretion
has been a key determinant of worsening glucose tolerance
following renal transplantation [2]. The risk factors for
NODAT include both the conventional risk factors for
T2DM [e.g., older recipient age, nonwhite ethnicity, family
history of diabetes, sedentary lifestyle, high body mass
index (BMI), and cytomegalovirus or hepatitis C virus
(HCV) infection] and those specific to transplant patients
(acute rejection incidence, high doses of corticosteroids, and
an immunosuppressive regimen with calcineurin inhibitors)
[4, 5].
Among the calcineurin inhibitors used in transplant recip-
ients, the diabetogenic effect of tacrolimus seems to be the
most pronounced. In one study, patients receiving tacroli-
mus had a significantly higher incidence of NODAT than
those not medicated with the drug [4]. In another study,
patients treated with tacrolimus had a significantly higher
incidence of NODAT or impaired fasting glucose after
6 months of therapy than those treated with cyclosporine
(33.4 vs. 26.0 %, respectively [6]. Tacrolimus has been
reported to cause NODAT through decreased insulin secre-
tion of pancreatic beta cells in an animal model, with inhi-
bition of insulin mRNA transcription [7]. Decreased insulin
release as a consequence of high tacrolimus concentration
was confirmed in human studies; however, insulin resis-
tance was also suggested as a possible mechanism [8, 9].
An elevated risk of developing NODAT has also been
described in prediabetic patients [9]. Hence, NODAT is
most probably not a separate entity but a consequence of
an underlying glucose metabolic disorder that is uncovered
by immunosuppression [5].
Past linkage studies have identified those genes associat-
ed with the most prominent T2DM effects, i.e., TCFL7,
PPARG, and KCNJ11. More recently genome-wide associ-
ation studies (GWAS) have confirmed previous reports and
uncovered dozens of new genetic variants associated with
an increased risk of T2DM [10–15]. A number of the single
nucleotide polymorphisms (SNPs) identified to be associat-
ed with T2DM are common in Caucasians and may underlie
individual susceptibility to NODAT. In some cases an asso-
ciation of T2DM risk alleles with NODAT has been con-
firmed. A polymorphism of the KCNQ1 gene, which
encodes the pore-forming subunit of the voltage-gated K+
channel, has been associated with an increased risk for
NODAT in Spanish Caucasians [16], independently of other
risk factors. Variants of hepatocyte nuclear family transcrip-
tion factor 4 alpha (HNF4A) and insulin receptor substrate-1
(IRS1) have been associated with NODAT among Hispanic
American renal allograft recipients, who are known to have
a higher risk of NODAT compared to other Caucasians,
despite early steroid withdrawal [17]. An influence of SNPs
within the calpain-10 gene (CAPN10) on the occurrence of
diabetes in Polish Caucasian kidney transplant recipients
has also been described [18]. Additionally, several diabeto-
genic alleles have been reported to be correlated with
NODAT risk in Koreans [19].
The aim of the study reported here was to analyze the
potential effect of SNPs previously associated with T2DM
on NODAT development in kidney transplant patients med-
icated with tacrolimus. For the purpose of this study, seven
SNPs in six genes, with the frequency of minor allele being
>0.1 in Caucasians, which had been previously identified
and confirmed as ‘diabetogenic’ in the general population in
GWAS studies were selected: rs4402960 and rs1470579 in
the IGF2BP2 intronic region, rs1111875 in near HHEX,
rs10811661 upstream of CDKN2A/B, rs13266634 missense




A total of 235 kidney transplant patients, all Polish Cauca-
sians and non-diabetic at the moment of transplantation
(patients with diabetes mellitus prior to the transplantation
were excluded) were eligible for enrollment in this retro-
spective study. Subjects were recruited consecutively from
patients who underwent kidney transplantation in the Clin-
ical Department of Nephrology and Dialysis, County Hos-
pital, Szczecin, Poland between 2000 and 2009 and who
were subsequently medicated with twice-daily tacrolimus
(Prograf; Astellas Pharma, Tokyo, Japan) as a part of im-
munosuppressive regimen. Patients who did not maintain
graft function for at least 1 year post-transplant were ex-
cluded. The patients eligible for enrollment were subdivided
into two groups: those with NODAT (n067) and the con-
trols, i.e., without NODAT (n0168). The characteristics of
the patients are given in Table 1. Patients with hemoglobin
A1c continuously >6.5 mg/dL, fasting plasma glucose of
>126 mg/dL (7.0 nmol/L), or those requiring insulin and/or
oral hypoglycemic agents for >3 months were diagnosed as
having NODAT. NODAT was diagnosed up to 1 year post-
transplantation. The observation time was extended in the
case of some late-onset NODAT patients in order to achieve
the 3-month evaluation period from the onset of diabetes.
The NODAT patients were subsequently divided into two
groups: those with early-onset NODAT (n039), in whom
diabetes occurred within the first 2 weeks of immunosup-
pressive therapy, and those with late-onset NODAT, in
whom diabetes was found later in the course of treatment
(n028).
The treatment protocol consisted of tacrolimus, myco-
phenolate mofetil, and steroids. Specifically, tacrolimus
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therapy was initiated at 0.1 mg/kg/day with doses adjusted
to maintain trough levels of between 10 and 12 ng/mL in the
first month post-transplantation, and then between 8 and
10 ng/mL. Whole blood tacrolimus concentration was
assessed with the use of a chemiluminescent microparticle
immunoassay (CMIA; Architect Tacrolimus Assay, Abbott,
Germany). An initial oral dose of mycophenolate mofetil
2.0 g/day was administered once daily or given in equally
divided doses every 12 h. Methylprednisolone was given
concomitantly: a dose of 500 mg on the day of surgery,
tapered to 40 mg/day during the first week, followed by
30 mg/day of prednisolone in the second week, 20 mg/day
of prednisolone in the third week, 15 mg/day in the fourth
week, and 10 mg/day thereafter. Total corticosteroid dose
for each patient during the first year of the study was
calculated, and methylprednisolone was recalculated to
prednisolone using r01.25 cofactor. All patients gave writ-
ten informed consent to participate in the study, and a
relevant ethics committee approved the study protocol.
Genotyping
Genomic DNA was extracted from 200 μL of whole blood
samples using the GeneMATRIX Quick Blood DNA Purifi-
cation kit (EURx, Gdansk, Poland). Pre-validated allelic dis-
crimination TaqMan real-time PCR assays (Applied
Biosystems, Foster City, CA) were used to detect SNPs pre-
viously associated with T2DM in the general population. The
following SNPs in their respective genes were analyzed (assay
IDs are given in parentheses): rs4402960 (C___2165199_10)
and rs1470579 (C___2165184_10) in IGF2BP2, rs1111875
( C _ _ 1 1 2 1 4 5 8 1 _ 1 0 ) i n HHEX , r s 1 0 8 1 1 6 6 1
(C__31288917_10 ) i n CDKN2A , r s 1 3266634
(C_ _ _ _ 3 5 7 8 8 8 _ 1 0 ) i n SLC30A8 , r s 1 8 0 1 2 8 2
( C _ _ _ 11 2 9 8 6 4 _ 1 0 ) i n PPARG , a n d r s 5 2 1 5
(C___2991148_10) in KCNJ11. Fluorescence data were cap-
tured using an ABI PRISM 7500 FAST Real-Time PCR
System (Applied Biosystems) after 40 cycles of PCR.
Statistical analysis
Categorical variables (i.e., allele, genotype, haplotype fre-
quencies, acute rejection episodes) were compared by the
Fisher exact test and chi-square test. Odds ratios (OR) and
95 % confidence intervals (95 % CI) were calculated using
the Newcombe–Wilson method without the continuity cor-
rection. Multivariate logistic regression model was used to
test independent NODAT risk factors. Variables identified as
potentially significant (p<0.1) were included in multivariate
analysis (age, BMI, acute rejection episodes, total steroid
dose) together with the sum of alleles previously associated
with increased risk of T2DM in the general population:
IGF2BP2 rs4402960 T, HHEX rs1111875T, CDKN2A
rs10811661 C , SLC30A8 rs13266634 C, PPARG
rs1801282 C, and KCNJ11 rs5215 C. The TCF7L2
rs7903146 T allele was added to the multivariate analysis,
as genotyping data were available from our previous study
for all patients [20] and this SNP has also been associated
with T2DM [21]. IGF2BP2 rs1470579 C was not further
analyzed, as it was found to be in almost complete linkage
disequilibrium with IGF2BP2 rs4402960 T (D′01.0, r20
0.981), forming a common haplotype that includes minor
alleles for both loci. Hence, it could not be considered as an
independent variable. In each patient, the number of ‘diabe-
togenic’ alleles was calculated for a given SNP (i.e., 0, 1, or
2), and values for all SNPs were subsequently summarized
to obtain a total number of ‘diabetogenic’ alleles. A p level
of <0.05 was considered to be statistically significant. The
data were tested for their fit to Hardy–Weinberg equilibrium
by calculating expected frequencies of genotypes and com-
paring them to the observed values using a chi-square test.
All calculations were performed using the Statistica 9.0
software package (Statsoft, Tulsa, OK).
Results
Mean patient’s age, BMI, and total steroid dose were higher
in the NODAT group than in the non-NODAT patients
(controls). No differences in gender, donor age, viral infec-
tion frequency, nor acute rejection episodes were noted
between these two groups (Table 1). In terms of genotype
frequency distribution, none of the SNPs analyzed showed a
significant deviation from the Hardy–Weinberg equilibrium.
Table 1 Characteristics of patients enrolled in the study
Patient characteristics NODAT (n067) No PTDM (n0168) p
Age (years) 47.7±10.6 43.2±13.0 0.014b
Sex (female) 30 (45.5) 78 (46.4) 1.000c
Body mass index 25.8±4.1 24.3±3.7 0.006b
Donor age (years) 47.8±11.8 46.0±12.3 0.321b
Viral infectionsa 10 (15.2) 27 (16.1) 1.000c
Acute rejection 9 (13.6) 10 (6.0) 0.064c
Steroid total dose (g) 4.20±1.72 3.76±2.35 0.017d
NODAT, New-onset diabetes after transplantation; PTDM, post-
transplant diabetes mellitus
Data are presented as the mean ± standard deviation, or as the number,
with the percentage in parenthesis
a Viral infections were: cytomegalovirus (6 vs. 20 in PTDM and control
group, respectively), hepatitis C virus (2 vs. 4), and hepatitis B virus (2
vs. 3)
b Student t test
c Fisher exact test
dMann–Whitney U test
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None of the analyzed SNPs was significantly associated
with the risk of NODAT (Table 2). However, of the seven
SNPs analyzed, six (with the exception for KCNJ11 rs5215)
alleles previously identified as T2DM risk factors occurred
more frequently in the NODAT group than in patients who
did not develop diabetes (difference was not significant).
The NODAT patients were subsequently divided into those
with early-onset NODAT (n039) and late-onset NODAT
(n028), respectively. No association between genetic factors
and early-onset NODAT was observed, although the
IGF2BP2 rs4402960 T allele was found significantly more
frequently among patients diagnosed with NODAT later
than 2 weeks post-transplantation (p00.048; Table 2). Of
the seven analyzed ‘diabetogenic’ alleles, six were more
frequent in the late-onset NODAT patients than in the
patients without diabetes (exception: the PPARG
rs1801282 C allele). Due to the small number of patients
in the subgroups, these differences were not significant. In
order to investigate a cumulative effect of SNPs previously
associated with T2DM in relation to NODAT, we analyzed
the total number of ‘diabetogenic’ alleles inherited by each
patient. The mean number of analyzed alleles tended to be
lower in patients without NODAT (6.19±1.71) than in all
NODAT patients (6.58±1.1.95; p00.09) and to be signifi-
cantly reduced in comparison with late-onset NODAT
patients (7.03±1.88; p00.018). Multivariate analysis con-
firmed the significance of ‘diabetogenic’ allele number in
the risk of developing late-onset NODAT (OR 1.37, 95 %
CI:1.05–1.78; p00.017), which was also influenced by the
occurrence of graft rejection episodes (Table 3). The sum of
alleles was not associated with early-onset NODAT (OR
1.03, 95 % CI 0.83–1.27; p00.801), rather, steroid total
dose was identified as a main independent risk factor. Ad-
ditionally, when patients were classified according to the
number of alleles previously associated with T2DM, those
carrying more than a half of ‘diabetogenic’ alleles (>7 of the
14 alleles within 7 genes) were at significantly higher risk of
NODAT (OR 2.17, 95 % CI 1.18–3.99; p00.015; Fig. 1).
Discussion
Both NODAT and T2DM share several risk factors (i.e.,
overweight or obesity, recipient age, Hispanic and African-
American ethnicity, CMVor HCV infection, age >40 years).
Genetic factors may also play an important role, since a
family history of T2DM among first-degree relatives has
been identified as a NODAT risk factor [4]. In our study, we
analyzed the potential effect of SNPs previously associated
with T2DM on NODAT development in kidney transplant
patients medicated with tacrolimus. An association between
the SNPs investigated and T2DM was definitely confirmed,
but their effect was relatively mild, with the odds ratios for
most variants ranging from 1.10 to 1.20, with a maximum of
about 1.4 for TCF7L2 rs7903146 T. TCF7L2 rs7903146 T is
the most prominent of all T2DM-associated common poly-
morphisms identified to date [13, 22]. It is clear that one
cannot detect the magnitude of the effects of these poly-
morphisms without analyzing thousands of patients. How-
ever, as the incidence of diabetes among transplant
recipients medicated with tacrolimus is much higher than
that in the general population, we had actually expected the
influence of the investigated genetic variants on NODAT
risk to be much more pronounced, as found by Yang et al.
who observed an adjusted odds ratio value of ≥2 for SNPs
within HNF4A and IRS1 genes among Hispanic American
kidney transplant recipients [17]. A study of Korean patients
confirmed the association of eight SNPs in six genes (i.e.,
TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, and
KCNQ1) with NODAT in subjects medicated according to
different immunosuppressive regimens (NODAT developed
at different times during the observation period, with a
median follow-up of >10 years) in a relatively large cohort
of kidney transplant recipients. However, a long observation
time might lead to an overlap of NODAT and T2DM in a
later post-transplant period. The significance of analyzed
variants could not be confirmed in our study, possibly due
to the different ethnicity of the study participants, but also
partly due to the limited number of patients analyzed, which
is certainly one of the limitations of our study. The number
of participants was limited as only patients receiving tacro-
limus were included. Tacrolimus is known to increase the
risk of NODAT in kidney allograft recipients compared to
other immunosuppressants [4, 6]. The majority of studies
performed to date on the association of genetic factors with
NODAT have included all patients regardless of immu-
nosuppressive regimen [17, 19, 23]. In this respect, the
group analyzed in our study is more homogenous, as all
study participants were treated according to the same
regimen (tacrolimus + mycofelate mofetil + steroids),
which may translate into an increased sensitivity of the
analysis.
Our investigation of the risk factors for early-onset NODAT
(developed in the first 2 weeks post-transplantation) and late-
onset NODAT revealed significant differences between these
subgroups of patients. Total steroid dose, including methyl-
prednisone administered as an induction of immunosuppres-
sive therapy, significantly increased the risk of diabetes in the
former group (early-onset) but not in the latter one. Indeed,
mean steroid dose in the first week post-transplantation was
significantly higher in early-onset NODAT patients (35.3±
6.9 mg/day prednisolone) than in patients without NODAT
(31.5±8.5 mg/day prednisolone; p00.017) as well as to the
late-onset NODAT group (31.3±7.7 mg/day prednisolone; p0
0.031). This observationmay indicate that early-onset NODAT
is triggered rather by steroids, while late-onset NODAT is
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probably more dependent on other risk factors. The frequency
of acute rejection episodes and total steroid dose are known to
be associated with PTDM and are usually linked since high
methylprednisolone doses (pulse therapy) are administered in
the case of graft rejection. In our study, multivariate analysis
revealed the occurrence of acute rejection episodes as an
independent late-onset NODAT risk factor, while steroid dose
was the only adjusted risk factor of early-onset NODAT.
However, some patients received monoclonal antibodies in-
stead of steroids during an acute rejection episode, which may
explain the observed differences.
In order to investigate the cumulative effect of SNPs
previously associated with T2DM on NODAT occur-
rence, we assessed the total number of ‘diabetogenic’
alleles inherited by each patient. Summing up the alleles
of different genes would seem to be an acceptable ap-
proach since the effect of each SNP on T2DM risk is
comparable [13, 22, 24, 25]. Our analysis revealed that
individuals carrying more than half of the total possible
number of ‘diabetogenic’ alleles (>7 of the 14 alleles of
7 genes) were at a significantly higher risk of NODAT,
primarily due to an increased risk of late-onset NODAT
in patients inheriting a greater number of ‘risk’ alleles.
These findings were also confirmed in the multivariate
analysis, where the sum of ‘diabetogenic’ alleles was
revealed as a significant risk factor for late-onset—but
not early-onset—NODAT. Based on the results of our
study, we conclude that the effect of common polymor-
phisms in IGF2BP2, HHEX, CDKN2A/B, SLC30A8,
PPARG, and KCNJ11, all of which have been previously
associated with T2DM, is not pronounced in the risk of
NODAT in kidney transplant recipients treated with
tacrolimus. However, the sum of ‘diabetogenic’ alleles
may be one of the factors increasing the incidence of
post-transplant diabetes, especially in the case of late-
onset NODAT, which seems to be less dependent on
steroid treatment. Our results support the observation that
a complex analysis of diabetes risk genotypes may lead
to the identification of disease susceptibility predictors,
also for NODAT, and that this approach may have an
advantage over single-locus studies [26]. Finally, the
application of the analyzed genetic markers in therapy
individualization should be verified by further indepen-
dent studies in populations of different ethnicities.
Table 3 Multivariate logistic regression analysis of potential risk factors for early-onset and late-onset NODAT
Independent variables Early NODAT (n039) Late NODAT (n028)
OR (95 % CI) p OR (95 % CI) p
Patient’s age 1.02 (0.99–1.05) 0.181 1.02 (0.99–1.06) 0.206
BMI (kg/m2) 1.05 (0.95–1.16) 0.315 1.11 (0.99–1.24) 0.074
Acute rejection episodes 0.76 (0.17–3.40) 0.724 5.47 (1.55–19.22) 0.008
Steroid total dosea 2.40 (1.05–5.51) 0.037 0.93 (0.50–1.72) 0.801
Sum of the risk allelesb 1.03 (0.83–1.27) 0.801 1.37 (1.05–1.78) 0.017
Early NODAT, up to 14 days post-transplantation; late-onset NODAT, developed later than 14 days post-transplantation
a Logarithmic transformation applied to fit normal distribution
b Sum of alleles previously associated with T2DM: IGF2BP2 rs4402960 T, HHEX rs1111875 C, CDKN2A/B rs10811661 T, SLC30A8 rs13266634
C, PPARG rs1801282 C, KCNJ11 rs5215 C, and TCF7L2 rs7903146 T
Fig. 1 Incidence of new-onset diabetes after transplantation (NODAT)
in relation to the sum the alleles previously associated with type 2
diabetes mellitus (T2DM) (IGF2BP2 rs4402960 T, HHEX rs1111875
C, CDKN2A/B rs10811661 T, SLC30A8 rs13266634 C, PPARG
rs1801282 C, KCNJ11 rs5215 C, and TCF7L2 rs7903146 T). Asterisk
indicates significance between patients inheriting ≤7 vs. >7 alleles in
relation to overall NODAT incidence, calculated by means of Fisher
exact test (odds ratio 2.17, 95 % confidence interval 1.18–3.99)
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